SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of White River Capital, Inc. (RVR), BioMimetic Therapeutics Inc. (BMTI) , Jeffries Group, Inc. (JEF) and Provectus Pharmaceuticals,

NEW YORK, Nov. 21, 2012

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

White River Capital, Inc.
Levi & Korsinsky is investigating the Board of Directors of White River Capital, Inc. (NYSE MKT: RVR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company and its subsidiary, Coastal Credit, LLC, to an affiliate of Parthenon Capital Partners for $23 per share.

Click here to learn more about the investigation http://zlk.9nl.com/white-river-capital-rvr.  

BioMimetic Therapeutics Inc.
Levi & Korsinsky is investigating the Board of Directors of BioMimetic Therapeutics Inc. (NasdaqGS: BMTI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Wright Medical Group Inc. (NasdaqGS: WMGI) under which shareholders BioMimetic shareholders will receive $1.50 in cash and 0.2482 shares of Wright common stock for each share of BioMimetic stock they own.

Click here to learn more about the investigation http://zlk.9nl.com/biomimetic-bmti.  

Jeffries Group, Inc.
Levi & Korsinsky is investigating the Board of Directors of Jeffries Group, Inc. (NYSE: JEF) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to its largest shareholder, Leucadia National Corp. (NYSE: LUK) under which shareholders will receive 0.81 Leucadia shares for each share of Jefferies stock they own, representing an approximate value of $17.24 per share. At least one analyst set a price target of $19.00 per Jefferies share.